JP2011207882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011207882A5 JP2011207882A5 JP2011075243A JP2011075243A JP2011207882A5 JP 2011207882 A5 JP2011207882 A5 JP 2011207882A5 JP 2011075243 A JP2011075243 A JP 2011075243A JP 2011075243 A JP2011075243 A JP 2011075243A JP 2011207882 A5 JP2011207882 A5 JP 2011207882A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- absent
- antibody
- administering
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62016104P | 2004-10-19 | 2004-10-19 | |
| US60/620,161 | 2004-10-19 | ||
| US10/982,440 US7658924B2 (en) | 2001-10-11 | 2004-11-04 | Angiopoietin-2 specific binding agents |
| US10/982,440 | 2004-11-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538066A Division JP2008520188A (ja) | 2004-10-19 | 2005-10-19 | アンジオポエチン−２特異的結合物質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013190316A Division JP2014040428A (ja) | 2004-10-19 | 2013-09-13 | アンジオポエチン−２特異的結合物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011207882A JP2011207882A (ja) | 2011-10-20 |
| JP2011207882A5 true JP2011207882A5 (enExample) | 2012-06-21 |
Family
ID=39608222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538066A Pending JP2008520188A (ja) | 2004-10-19 | 2005-10-19 | アンジオポエチン−２特異的結合物質 |
| JP2011075243A Withdrawn JP2011207882A (ja) | 2004-10-19 | 2011-03-30 | アンジオポエチン−２特異的結合物質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538066A Pending JP2008520188A (ja) | 2004-10-19 | 2005-10-19 | アンジオポエチン−２特異的結合物質 |
Country Status (10)
| Country | Link |
|---|---|
| JP (2) | JP2008520188A (enExample) |
| CN (1) | CN101495513B (enExample) |
| BR (1) | BRPI0518209A (enExample) |
| EA (1) | EA011866B1 (enExample) |
| IL (1) | IL182279A0 (enExample) |
| MA (1) | MA29015B1 (enExample) |
| MX (1) | MX2007004247A (enExample) |
| RU (2) | RU2404992C2 (enExample) |
| SG (1) | SG156668A1 (enExample) |
| ZA (1) | ZA200704020B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0518209A (pt) * | 2004-10-19 | 2008-11-04 | Amgen Inc | agentes de ligação especìficos à angiopoietina-2 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| EA022546B1 (ru) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Способ торможения роста карциномы эрлиха у лабораторного животного |
| DK2760471T3 (en) * | 2011-09-30 | 2017-05-08 | Dana Farber Cancer Inst Inc | THERAPEUTIC PEPTIDES |
| KR102063028B1 (ko) * | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| WO2014100834A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| CN106512006A (zh) * | 2016-07-25 | 2017-03-22 | 广州道瑞医药科技有限公司 | Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用 |
| CN106075448A (zh) * | 2016-07-25 | 2016-11-09 | 广州道瑞医药科技有限公司 | Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CN109096368B (zh) * | 2018-09-30 | 2021-07-20 | 华南理工大学 | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 |
| US20220204603A1 (en) * | 2019-02-25 | 2022-06-30 | Pharmabcine Inc. | Anti-ang2 antibody and use thereof |
| CN112126671B (zh) * | 2020-08-18 | 2021-08-31 | 中山大学附属第五医院 | 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用 |
| CN116265487B (zh) * | 2021-12-16 | 2025-01-10 | 三优生物医药(上海)有限公司 | 抗ang2-vegf双特异性抗体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514434A (en) * | 1999-03-26 | 2003-11-28 | Univ California | Modulation of vascular permeability by means of TIE2 receptor activators |
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| PT1292335E (pt) * | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| CA2473970C (en) * | 2001-10-12 | 2013-05-28 | Monosolrx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| BRPI0518209A (pt) * | 2004-10-19 | 2008-11-04 | Amgen Inc | agentes de ligação especìficos à angiopoietina-2 |
-
2005
- 2005-10-19 BR BRPI0518209-3A patent/BRPI0518209A/pt not_active IP Right Cessation
- 2005-10-19 RU RU2007118670/13A patent/RU2404992C2/ru not_active IP Right Cessation
- 2005-10-19 EA EA200700876A patent/EA011866B1/ru not_active IP Right Cessation
- 2005-10-19 CN CN200580043569.5A patent/CN101495513B/zh not_active Expired - Fee Related
- 2005-10-19 SG SG200907008-7A patent/SG156668A1/en unknown
- 2005-10-19 MX MX2007004247A patent/MX2007004247A/es active IP Right Grant
- 2005-10-19 JP JP2007538066A patent/JP2008520188A/ja active Pending
-
2007
- 2007-03-28 IL IL182279A patent/IL182279A0/en unknown
- 2007-05-11 MA MA29892A patent/MA29015B1/fr unknown
- 2007-05-18 ZA ZA200704020A patent/ZA200704020B/en unknown
-
2010
- 2010-08-05 RU RU2010132956/10A patent/RU2010132956A/ru not_active Application Discontinuation
-
2011
- 2011-03-30 JP JP2011075243A patent/JP2011207882A/ja not_active Withdrawn